Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

NCT02539719 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

74

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic Considerations

Conditions

Ovarian Cancer

Interventions

DRUG: SC-003
DRUG: SC-003 in combination with ABBV-181

Sponsor

Stemcentrx